Agilent Technologies (A) DCF: History & Chart

Agilent Technologies, Inc.(A)

Medical - Diagnostics & Research · Santa Clara, CA

$146.85-4.01 (-2.66%)

At close: Sep 8, 2026 (market close, ET)

About Agilent Technologies, Inc.

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Santa Clara, CA

18,000 employees

www.agilent.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Padraig McDonnell

View full financials

Agilent Technologies, Inc. (A) DCF Valuation

Price is ABOVE the estimated range

$43.08

$73.81

Model scenario range

$146.85

Today's price

TGM's two-stage DCF values Agilent Technologies, Inc. (A) between $43.08 and $73.81 depending on assumptions, with a base case of $55.43. Growth is taken from the company's own record (blend of 5-year revenue and FCF growth), fading to 2.5% long-run; the discount rate (10.2%) reflects its beta.

What would today's price require?

Growth the price assumes+26.6%/yr

Actual FCF growth, last 5 years+2.5%/yr

$146.85 is justified only if free cash flow grows about +26.6% a year (fading to 2.5% long-run) at a 10.2% required return — faster than the company has actually grown.

Scenario	FCF growth (fading to 2.5%)	Discount	Value / share
Conservative	0.5%/yr	11.2%	$43.08
Base case	3.1%/yr	10.2%	$55.43
Optimistic	6.1%/yr	9.2%	$73.81
Third-party model estimate (FMP)	independent reference · retrieved Sep 9, 2026 · assumptions not provided		$71.80

The FMP figure is a third-party point estimate. Its cash-flow forecast, discount rate, terminal growth, and valuation date are not included in the stored response, so TGMCharts presents it only as a reference—not as an intrinsic-value conclusion or price target.

Price|PE Ratio|FCF Yield|All Metrics

Current Price

$146.85

Market-Implied Growth

+26.6%/yr

vs +2.5% 5Y actual

Model Scenario Range

$43.08 – $73.81

model output — not a price target

A DCF Fair Value Calculator

Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for A (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.

FCF Growth Rate3.1%/yr

Historical FCF CAGR: 3Y -0.9% · 5Y 2.5% · 10Y 7.7%

Discount Rate (WACC)10.2%

Terminal Growth2.5%

Projection Years10yr

Base inputs: FCF $1.3B · 0.28B shares · net debt $1.6B

Estimated Fair Value

$55.43

-62.3% vs $146.85

Current price$146.85

Third-party model estimate (FMP)$71.80

Sensitivity — fair value by discount rate × terminal growth

How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 3.1%/yr FCF growth and 10-year horizon fixed. Green = above today's $146.85; red = below. Your current case is outlined.

WACC ↓ / Terminal →	1.50%	2.00%	2.50%	3.00%	3.50%
8.2%	$66.86	$71.49	$76.92	$83.38	$91.21
9.2%	$57.37	$60.72	$64.57	$69.03	$74.27
10.2%	$50.07	$52.59	$55.43	$58.67	$62.38
11.2%	$44.27	$46.22	$48.40	$50.83	$53.58
12.2%	$39.56	$41.11	$42.81	$44.70	$46.80